Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

KYTX

Kyverna Therapeutics Inc.

Last Close
May 31 • 04:00PM ET
12.53
Dollar change
+0.21
Percentage change
1.70 		%
Held by: VXF SCHA VTI ITOT SCHB IBRN BMED Scroll to Statements
Index- P/E- EPS (ttm)- Insider Own54.80% Shs Outstand43.12M Perf Week0.80%
Market Cap540.29M Forward P/E- EPS next Y-4.12 Insider Trans9.57% Shs Float19.47M Perf Month-24.56%
Income- PEG- EPS next Q-0.74 Inst Own38.55% Short Float14.04% Perf Quarter-54.85%
Sales- P/S- EPS this Y96.08% Inst Trans- Short Ratio6.95 Perf Half Y-
Book/sh8.37 P/B1.50 EPS next Y-17.45% ROA- Short Interest2.73M Perf Year-
Cash/sh8.58 P/C1.46 EPS next 5Y- ROE- 52W Range12.01 - 35.06 Perf YTD-58.23%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-64.26% Beta-
Dividend TTM- Quick Ratio17.17 Sales past 5Y-37.90% Gross Margin- 52W Low4.33% ATR (14)1.37
Dividend Ex-Date- Current Ratio17.17 EPS Y/Y TTM- Oper. Margin- RSI (14)34.92 Volatility9.04% 10.21%
Employees96 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price42.75
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q- Payout- Rel Volume1.06 Prev Close12.32
Sales Surprise- EPS Surprise-33.33% Sales Q/Q- EarningsMay 14 AMC Avg Volume393.26K Price12.53
SMA20-10.84% SMA50-32.30% SMA200-43.38% Trades Volume416,933 Change1.70%
Date Action Analyst Rating Change Price Target Change
Mar-04-24Initiated Wells Fargo Overweight $44
Mar-04-24Initiated Morgan Stanley Overweight $40
Mar-04-24Initiated Leerink Partners Outperform $48
Mar-04-24Initiated JP Morgan Overweight $39
May-14-24 10:54PM
KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024
(InvestorPlace) +5.95%
04:05PM
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
(PR Newswire)
Apr-11-24 05:01PM
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
(PR Newswire)
Mar-29-24 02:59PM
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
(PR Newswire)
Mar-26-24 04:05PM
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
(PR Newswire) +6.97%
07:00AM Loading…
Mar-14-24 07:00AM
Why That Hot Biotech IPO Could Be a Winner
(The Wall Street Journal)
Mar-07-24 07:26PM
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
(PR Newswire)
06:14PM
How Kyverna is positioned for success on autoimmune therapy: CEO
(Yahoo Finance Video)
Feb-12-24 04:39PM
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
(PR Newswire)
Feb-07-24 10:29PM
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
(PR Newswire)
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jones Ryan AlexanderChief Financial OfficerMay 28 '24Option Exercise0.7318,01613,15243,950May 29 04:33 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
Northpond Ventures III GP, LLCFormer 10% OwnerFeb 12 '24Buy22.00450,0009,900,000450,000Feb 12 05:51 PM
Bain Capital Life Sciences Inv10% OwnerFeb 12 '24Buy22.00450,0009,900,0003,163,868Feb 14 05:26 PM
Vida Ventures, LLC10% OwnerFeb 12 '24Buy22.00253,1365,568,992252,553Feb 14 07:04 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.